Currently, the phase 3 study of tamibarotene and azacitidine combination therapy for RARα-high high-risk MDS patients (NCT04797780), and a phase 2 study of tamibarotene plus venetoclax/azacitidine for newly diagnosed RARα-high AML patients (NCT04905407), are ongoing (Table 1). This evidence concerns the gene RARA and myelodysplastic syndrome.